Qiagen (QGEN) Surpasses Q1 Earnings and Revenue Estimates

29.04.24 23:25 Uhr

Werte in diesem Artikel
Aktien

38,80 EUR 0,30 EUR 0,77%

Indizes

PKT PKT

18.143,7 PKT -110,5 PKT -0,61%

6.970,0 PKT -42,7 PKT -0,61%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

183,4 PKT -1,0 PKT -0,54%

504,6 PKT -4,4 PKT -0,86%

9.629,7 PKT -64,8 PKT -0,67%

18.142,0 PKT -105,0 PKT -0,58%

18.228,0 PKT -5,9 PKT -0,03%

3.304,8 PKT 7,0 PKT 0,21%

7.123,6 PKT -45,9 PKT -0,64%

3.281,1 PKT -30,3 PKT -0,92%

2.404,1 PKT -22,4 PKT -0,92%

3.676,1 PKT -33,8 PKT -0,91%

Qiagen (QGEN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.55%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.56 per share when it actually produced earnings of $0.55, delivering a surprise of -1.79%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Qiagen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $458.8 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 0.73%. This compares to year-ago revenues of $485.4 million. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Qiagen shares have lost about 7% since the beginning of the year versus the S&P 500's gain of 6.9%.What's Next for Qiagen?While Qiagen has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Qiagen: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.51 on $494.99 million in revenues for the coming quarter and $2.09 on $2 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Revance Therapeutics, Inc. (RVNC), another stock in the same industry, has yet to report results for the quarter ended March 2024.This company is expected to post quarterly loss of $0.66 per share in its upcoming report, which represents a year-over-year change of +10.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.Revance Therapeutics, Inc.'s revenues are expected to be $55.64 million, up 12.8% from the year-ago quarter.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN): Free Stock Analysis Report Revance Therapeutics, Inc. (RVNC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf QIAGEN

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf QIAGEN

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu QIAGEN N.V.

Analysen zu QIAGEN N.V.

DatumRatingAnalyst
18.06.2024QIAGEN NeutralUBS AG
18.06.2024QIAGEN BuyDeutsche Bank AG
18.06.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
21.05.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
02.05.2024QIAGEN NeutralUBS AG
DatumRatingAnalyst
18.06.2024QIAGEN BuyDeutsche Bank AG
18.06.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
21.05.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.04.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.04.2024QIAGEN BuyDeutsche Bank AG
DatumRatingAnalyst
18.06.2024QIAGEN NeutralUBS AG
02.05.2024QIAGEN NeutralUBS AG
02.05.2024QIAGEN NeutralUBS AG
30.04.2024QIAGEN NeutralUBS AG
30.04.2024QIAGEN HoldJefferies & Company Inc.
DatumRatingAnalyst
17.02.2021QIAGEN VerkaufenIndependent Research GmbH
14.12.2020QIAGEN VerkaufenDZ BANK
10.12.2020QIAGEN VerkaufenIndependent Research GmbH
24.11.2020QIAGEN VerkaufenIndependent Research GmbH
11.11.2020QIAGEN VerkaufenDZ BANK

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für QIAGEN N.V. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"